Steve Harr's Net Worth

$91.9 Million

Estimate Recalculated Sep 8, 2024 07:32PM EST

Who is Steve Harr?

Steve Harr has an estimated net worth of $91.9 Million. This is based on reported shares across multiple companies, which include Sana Biotechnology, Inc., Loxo Oncology, Inc., and Juno Therapeutics, Inc..

SEC CIK

Steve Harr's CIK is 0001627387

Past Insider Trading and Trends

2017 was Steve Harr's most active year for acquiring shares with 7 total transactions. Steve Harr's most active month to acquire stocks was the month of February. 2018 was Steve Harr's most active year for disposing of shares, totalling 12 transactions. Steve Harr's most active month to dispose stocks was the month of February. 2017 saw Steve Harr paying a total of $228,900.00 for 228,423 shares, this is the most they've acquired in one year. In 2018 Steve Harr cashed out on 1,270,602 shares for a total of $47,331,429.96, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Sana Biotechnology, Inc. (SANA) Snapshot price: $5.05

President & CEO

Steve Harr owns 7,839,750 units of Common Stock which is worth $39,590,737.50. From 2022 to 2024 Steve Harr acquired a total of 2,031,250 shares in Sana Biotechnology, Inc., Steve also disposed a total of 334,000 shares of Sana Biotechnology, Inc..

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Mar 7
Form 4
—
0
—
—
0
Mar 2
Form 4
-4.09%
-334.00K
—
—
7.84M
Apr 14
Form 4
—
0
—
—
0
Mar 3
Form 4
+33.07%
2.03M
—
—
8.17M
Feb 8
Form 3
—
0
—
—
0
No matching records found

Loxo Oncology, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Feb 15
Form 4
—
0
—
—
0
Jun 13
Form 4
—
0
—
—
0
Jun 22
Form 4
—
0
—
—
0
Nov 7
Form 3
—
0
—
—
0
No matching records found

Juno Therapeutics, Inc. No price found

CFO & Head, Corp. Development

Steve Harr used to own units in Common Stock but no longer holds any shares there.acquired a total of 130,261 shares in Juno Therapeutics, Inc. at a cost of $228,900.00, Steve also disposed a total of 930,261 shares of Juno Therapeutics, Inc. equalling to $52,525,050.01.

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-639.52K
$87.00
—
0
Mar 5
Form 4
+1.84%
11.54K
—
—
639.52K
Feb 27
Form 4
-20.76%
-164.49K
$85.49
-$145,674.96
627.97K
Feb 7
Form 4
+3.82%
29.14K
—
—
792.47K
Jan 31
Form 4
—
0
$26.74
-$315,373.72
763.33K
Scheduled
Dec 21
Form 4
+4.93%
35.89K
—
—
763.33K
Oct 20
Form 4
—
0
$19.36
-$186,200.00
727.44K
Scheduled
Jul 3
Form 4
—
0
$19.36
-$186,200.87
727.44K
Scheduled
Jun 27
Form 4
+3.92%
27.44K
—
—
727.44K
Feb 7
Form 4
-4.11%
-30.00K
$43.32
-$1,299,529.65
700K
Scheduled
Jun 10
Form 4
-0.68%
-5.00K
$45.00
-$225,000.00
730K
Scheduled
Mar 4
Form 4
-3.92%
-30.00K
$37.58
-$1,127,341.65
735K
Scheduled
Mar 1
Form 4
—
0
—
—
0
Feb 2
Form 4
-4.38%
-35.00K
$46.43
-$1,625,074.16
765K
Scheduled
Dec 10
Form 4/A
—
0
—
—
0
Mar 3
Form 4
—
0
—
—
0
Mar 3
Form 3
—
0
—
—
0
No matching records found